A pharmaceutical product launch is the culmination of years of scientific, clinical, regulatory, and commercial investment. It is also the moment when delegation discipline is tested most severely. Every function in the organization has a stake in launch success, stakeholders demand CEO visibility and commitment, and the pressure to personally oversee critical launch activities is intense.
Pharma CEOs who fail to delegate effectively during launch create a paradox: by trying to ensure launch success through personal involvement, they divert the commercial, medical, and regulatory teams from the organized, high-cadence execution that actually produces launch success. This delegation framework provides a structured approach to CEO involvement in commercial launch that is visible enough to drive organizational energy without being so operational that it disrupts launch execution.
Framework Principles
Three principles should govern launch delegation for pharma CEOs:
The CEO signals priority, not direction: The CEO’s presence at key launch moments, such as the FDA approval announcement, the commercial team launch conference, and the investor day product spotlight, signals organizational priority. These are communications and culture moments, not management moments. The CEO is not directing launch execution; they are amplifying the significance of what the commercial team is executing.
All launch execution belongs to the CCO: The Chief Commercial Officer or Chief Marketing Officer is the CEO’s complete delegate for launch execution. This means the CCO makes decisions about promotional strategy, sales force deployment, payer strategy, and market development without seeking CEO approval for each decision. The CEO sets the outcome expectations; the CCO designs and executes the strategy to meet them.
Exception-based CEO involvement in launch operations: The CEO participates in launch operations only when a decision is genuinely beyond the CCO’s authority, when a situation requires CEO-level relationship, or when a decision has board or investor implications that require executive judgment. Everything else belongs to the launch team.
Role Definitions for Launch Delegation
CEO:
- Owns the investor relations narrative for the launch, including what success looks like and the key metrics to watch
- Conducts personal outreach to Key Opinion Leaders (KOLs) identified as critical to launch success, in coordination with Medical Affairs
- Represents the organization in launch-related press interviews and media opportunities
- Approves the overall launch investment budget and any significant mid-launch reallocation
- Reviews launch performance against milestones at the monthly leadership team meeting
- Makes final decisions on launch strategy changes that have significant commercial risk implications
Chief Commercial Officer:
- Owns the complete launch plan and its execution
- Chairs the Launch Steering Committee
- Manages commercial team readiness including training, deployment, and performance management
- Makes pricing and contracting decisions within board-approved parameters
- Manages payer strategy and key account planning
- Owns the commercial budget and makes in-period resource allocation decisions within approved budget
Chief Medical Officer / Medical Affairs:
- Manages KOL engagement program and scientific communication
- Owns publication strategy and congress presence for the launch indication
- Coordinates medical education activities within compliance-approved frameworks
- Manages medical information response function
Head of Regulatory Affairs:
- Manages label negotiations and any post-approval commitment management
- Coordinates with commercial on label-compliant promotional claims
- Manages any post-marketing study commitments related to the approval
Head of Market Access:
- Leads payer strategy and national account engagement
- Manages formulary submission process
- Reports to CCO, coordinates with Medical Affairs on HEOR support
Decision Authority During Launch
The ambiguity of launch decision-making is a major source of CEO over-involvement. Eliminate ambiguity with an explicit launch decision authority framework:
CEO decision required:
- Public pricing announcements that set a market-defining precedent
- Any decision to delay a commercial launch beyond the planned date
- Voluntary market withdrawal or restriction during launch
- Board communication of any launch performance material deviation from forecast
- Significant commercial investment beyond the approved budget
CCO decision, CEO notification within 24 hours:
- Contracting decisions with formulary impact on major payers
- Sales force redeployment in response to competitive or market access developments
- Promotional strategy changes in response to significant KOL feedback or competitive data
- Any significant public relations issue related to the product in the launch period
CCO decision, no CEO notification required:
- Operational promotional decisions within approved messaging and budget
- Sales territory management and performance management actions
- Tactical payer engagement and contracting within approved parameters
- Marketing vendor and agency management
The Launch Steering Committee Structure
Every major pharmaceutical launch benefits from a Launch Steering Committee (LSC) that coordinates cross-functional launch execution. The CEO’s relationship to the LSC is a key delegation design question.
The CCO should chair the LSC, not the CEO. The LSC meets weekly during the 6 months before and 6 months after approval, and bi-weekly thereafter. The CEO attends the LSC quarterly to receive a strategic launch briefing and provide strategic direction. Between these appearances, the CEO receives a weekly launch dashboard from the CCO but does not attend LSC operations meetings.
This structure keeps the CEO informed through the dashboard and periodic strategic engagement while leaving launch operational decision-making fully in the CCO’s hands.
The Launch Dashboard for CEO Oversight
Design the CEO’s launch dashboard to provide strategic insight in 15 minutes of reading time. Essential elements:
Commercial performance: Net sales versus forecast, new-to-brand prescriptions versus target, market share versus forecast, days on therapy trends.
Market access: Number of covered lives, formulary position status (Tier 1/2/3 across key plans), payer pipeline for unrestricted access.
Sales force performance: Reach and frequency against target, prescription trends by sales territory segment, pull-through on key account targeting.
Medical Affairs: Number of KOL engagements, medical information request volume and themes, publication milestones.
Competitive intelligence: Any significant competitive developments affecting the launch market.
Each metric should include a color indicator (green/yellow/red) and a brief CMO or CCO comment on any yellow or red item. The CEO reviews this dashboard and provides feedback; the CCO acts on any CEO observations.
According to McKinsey analysis of pharmaceutical launch performance, companies that achieve top-quartile launch performance share a characteristic of strong functional leadership under clear CEO strategic direction, not heavy CEO operational involvement. The framework above is designed to replicate this pattern.
For context on how launch delegation connects to the ongoing commercial operations delegation structure, see pharma CEO delegation guide, which provides a comprehensive view of pharma CEO delegation across all commercial and operational functions.
Pre-Launch Delegation: The 18-Month Countdown
Launch delegation does not begin at approval. The 18-month period before anticipated approval is when the launch infrastructure must be built and the delegation structure established. During this period, the CEO should be investing in:
Commercial leadership quality: Is the CCO and commercial leadership team capable of executing a successful launch independently? If not, now is the time to make changes, not three months before launch.
Launch readiness reviews: Quarterly structured reviews of launch readiness across all functions, chaired by the CCO, attended by the CEO quarterly. The CEO’s role in these reviews is to ask hard questions about readiness and resource adequacy, not to direct readiness activities.
Payer strategy development: Early payer engagement is a CEO-level relationship matter in many major accounts. The CEO’s pre-launch payer engagement, coordinated by the Head of Market Access, should be planned as a specific CEO activity in the launch calendar.
Investor expectations: The CEO’s investor communication about the expected launch sets the performance expectations the company will be measured against. This narrative should be carefully calibrated with the CCO and CFO before being communicated publicly.
Post-Launch Delegation: Maintaining Discipline
Launch execution pressure tends to pull CEOs back into commercial operations when early results are disappointing. Resist this pull. A launch that is underperforming in its first quarter does not benefit from CEO operational involvement; it benefits from the CCO’s focused commercial problem-solving with appropriate resources and executive backing.
The CEO’s role when launch performance is below expectation is to ask the CCO: What is happening? What is your plan to address it? What do you need from me? The CEO then provides the resources and organizational backing the CCO needs to execute the recovery plan. This is appropriate oversight without operational rescue.
For detailed guidance on managing the drug pipeline delegation that leads to the launch moment, see pharma drug pipeline, which covers how pharma CEOs can maintain strategic visibility across the full development portfolio without operational enmeshment in any single program.
Related Reading
For further context, explore Delegation Framework for the 3PL Provider CEO and Delegation Framework for Academic Medical Center CEO.